Discontinuation report DEPO-PROVERA
| Report ID | 178960 |
| Drug Identification Number | 00585092 |
| Brand name | DEPO-PROVERA |
| Common or Proper name | MEDROXYPROGESTERONE ACETATE SUSPENSION |
| Company Name | PFIZER CANADA ULC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | MEDROXYPROGESTERONE ACETATE |
| Strength(s) | 150MG |
| Dosage form(s) | SUSPENSION |
| Route of administration | INTRAMUSCULAR INTRAMUSCULAR |
| Packaging size | 5 x 1mL |
| ATC code | G03AC |
| ATC description | HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2022-08-05 |
| Remaining supply date | 2022-08-05 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | As indicated on posting 131489, product in status CANCELLED POST MARKET. No more supply in Vial format for Depo-Provera. Other presentation available, pre-filled syringes (DIN 02523493). |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
| Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2022-12-20 | French | Compare |
| v1 | 2022-12-20 | English | Compare |
Showing 1 to 2 of 2